Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: russwinter who wrote (6275)	5/6/2002 11:38:59 AM
From: software salesperson	Respond to of 52153

cash value biotechs? sales bullmarket.com

To: russwinter who wrote (6275)	5/6/2002 1:22:48 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

It's quite unclear to me whether MAXM's Maxamine (or whatever it is they now call it) will be shown to have value or not. CRGN is much more interesting. They are in an out-of-favor sector (genomics), have a major partner with unclear prospects (Bayer), and have been very slow getting anything into the clinic. But they are indeed extraordinarily cheap on a fundamental basis - but you'll likely have to be very patient unless there is a complete turnaround in the sector's psychology. Note they also have some debt ($150m?) in the form of a busted convert. Peter